Clinical Trials Directory

Trials / Terminated

TerminatedNCT00695643

Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
345 (actual)
Sponsor
Dr. Falk Pharma GmbH · Industry
Sex
All
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to determine whether mesalazine granules compared to placebo is effective in prevention of recurrence of disease.

Detailed description

The purpose of the study is to demonstrate the superiority of mesalazine granules compared to placebo in terms of the primary efficacy variable proportion of recurrence-free patients within 48 weeks.

Conditions

Interventions

TypeNameDescription
DRUGMesalazine3 g per day
DRUGPlacebo0 g per day

Timeline

Start date
2008-01-01
Primary completion
2011-11-01
Completion
2012-01-01
First posted
2008-06-12
Last updated
2017-07-24

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00695643. Inclusion in this directory is not an endorsement.

Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis (NCT00695643) · Clinical Trials Directory